Cabergoline and Fluid retention - a phase IV clinical study of FDA data

Summary:

Fluid retention is reported as a side effect among people who take Cabergoline (cabergoline), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Coumadin, and have Acromegaly.

The phase IV clinical study analyzes which people have Fluid retention when taking Cabergoline. It is created by eHealthMe based on reports of 5,946 people who have side effects when taking Cabergoline from the FDA, and is updated regularly.

What is Cabergoline?

Cabergoline has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 6,257 Cabergoline users. Check the latest studies of Cabergoline.

What is Fluid retention?

Fluid retention (an abnormal accumulation of fluid in the blood) is found to be associated with 1,702 drugs and 2,446 conditions by eHealthMe. Check the latest studies of Fluid retention.

On Aug, 03, 2026

5,946 people reported to have side effects when taking Cabergoline.
Among them, 31 people (0.52%) have Fluid retention.

Could Cabergoline cause Fluid retention?

Among these 31 people:

How long have people been on Cabergoline when they have Fluid retention? *

What is the gender of people who have Fluid retention when taking Cabergoline? *

female: 51.72 %
male: 48.28 %

What is the age of people who have Fluid retention when taking Cabergoline? *

What are other drugs people take besides Cabergoline? *

What are other side effects people have besides Fluid retention? *

Fatigue (feeling of tiredness): 20 people, 64.52%
Joint Pain: 18 people, 58.06%
Injection Site Pain: 16 people, 51.61%
Weakness: 15 people, 48.39%
Oedema Peripheral (superficial swelling): 13 people, 41.94%
Weight Loss: 12 people, 38.71%
Weight Increased: 11 people, 35.48%
Back Pain: 11 people, 35.48%
Drowsiness: 11 people, 35.48%
Swelling: 11 people, 35.48%

What are the existing conditions these people have? *

Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 19 people, 61.29%
Restless Leg Syndrome (a powerful urge to move your legs): 5 people, 16.13%
Parkinson's Disease: 4 people, 12.90%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 9.68%
Neoplasm Malignant (cancer tumour): 2 people, 6.45%
Hormone Level Abnormal: 2 people, 6.45%
Blood Oestrogen Decreased: 2 people, 6.45%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 3.23%
Pain: 1 person, 3.23%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Cabergoline and have Fluid retention?

- Check whether Fluid retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabergoline:

Cabergoline (6,257 reports)

Fluid retention treatments and more:

Fluid retention (79,660 reports)

Browse all side effects of Cabergoline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid retention:

Fluid retention (1,702 drugs)

Browse all the conditions that are associated with Fluid retention:

Fluid retention (2,446 conditions)

Related publications that referenced our studies

Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .
Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Cabergoline) and Cabergoline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.